Drug Profile

Somatropin/mecasermin combination therapeutics - Genentech/Tercica

Alternative Names: Growth hormone/insulin-like growth factor-1; Increlex/NutropinAq; rhGH/rhIGF-1

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech; Tercica
Developer Ipsen Biopharmaceuticals; Tercica
Class Biological peptides; Growth factors; Growth hormones; Peptides
Mechanism of Action Insulin-like growth factor I stimulants; Somatotropin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Short stature; Somatotropin deficiency

Most Recent Events

16 Oct 2008 Tercica has been acquired by Ipsen
25 Jan 2008 Phase-II clinical trials in Short stature in children in USA (SC)
12 Jul 2007 Preclinical trials in Short stature in USA (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com